financetom
Market
financetom
/
Market
/
Pidilite shares in focus; CLSA retains 'sell', maintains estimates for FY23-24
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Pidilite shares in focus; CLSA retains 'sell', maintains estimates for FY23-24
Jan 28, 2022 12:41 AM

Shares of Indian adhesive manufacturing giant Pidilite Industries Ltd were in focus on Friday after brokerage firm CLSA cut FY22 earnings for the stock by 5 percent and largely maintained estimates for FY23-24.

Share Market Live

NSE

At 9:30 am, shares of Pidilite were trading 0.76 percent higher at Rs 2,480 on the BSE.

The brokerage retained a 'sell' call on Pidilite with a target price of Rs 2,115. The company's Q3 results were below expectations, and though its medium-term prospects look firm, its valuation is expensive, according to CLSA. The brokerage also noted that inflationary settings continue to impact margin.

Also Read: Pidilite Q3 Results: Revenue up 8.54% to Rs 2,850 crore, in line with estimates; net profit falls 4.34% to Rs359 crore

Pidilite on Tuesday reported a 19.5 per cent decline in its consolidated net profit to Rs 359.24 crore for the third quarter ended December 2021. The company had posted a Rs 446.43-crore profit in the corresponding period a year ago, Pidilite Industries said in a regulatory filing.

Revenue stood at Rs 2,850.7 crore for the quarter ended December 31, 2021, an 8.54 percent increase quarter-on-quarter, the company said in its quarterly earnings report. The revenue also increased 24 percent year-on-year from Rs 2,299 crore at the end of Q3FY21.

Also Read:

Larsen & Toubro, PNB, Tata Motors, Britannia and more: Top stocks to watch out for on Jan 28

This was largely in line with estimates and came on the back of a strong showing in its consumer and bazaar (adhesives, art and craft materials, etc) and B2B (industrial products) segments.

Credit Suisse too cut FY22-24 EPS for the adhesive manufacturing stock by 2-5 percent and believes margin pressure on Pidilite persists. The brokerage also believes that Pidilite’s growth lacks significantly and will remain slower than that of Asian Paints.

Catch all our live market updates here.

(Edited by : Akanksha Upadhyay)

First Published:Jan 28, 2022 9:41 AM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Centerra Gold Q2 Adjusted Profit Rises 14% on Higher Gold Prices; Advances Its Goldfield Project to Construction
Centerra Gold Q2 Adjusted Profit Rises 14% on Higher Gold Prices; Advances Its Goldfield Project to Construction
Aug 6, 2025
05:15 PM EDT, 08/06/2025 (MT Newswires) -- Centerra Gold ( CGAU ) shares were last seen up 1.7% in after-hours New York trading after the companyh on Wednesday said its second-quarter adjusted profit rose 14% as it said it will move forward on construction of its Goldfield project in Nevada. The company said its adjusted profit, excluding most one-time items,...
US STOCKS-Wall Street ends higher with Nasdaq up more than 1%, led by Apple
US STOCKS-Wall Street ends higher with Nasdaq up more than 1%, led by Apple
Aug 6, 2025
(Updates close with volume, share moves) * Apple ( AAPL ) to announce $100-billion pledge, says White House official * S&P 500 earnings reports continue to be better than expected * Indexes: Dow up 0.2%, S&P 500 up 0.7%, Nasdaq up 1.2% By Caroline Valetkevitch NEW YORK Aug 6 (Reuters) - U.S. stocks ended higher on Wednesday, led by a...
Research Alert: Mck Kicks Off Fy 26 With Eps/sales Beat; Guidance Raised On U.s. Pharma
Research Alert: Mck Kicks Off Fy 26 With Eps/sales Beat; Guidance Raised On U.s. Pharma
Aug 6, 2025
06:50 PM EDT, 08/06/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: MCK released Q1 FY 26 results above consensus, with adjusted EPS of $8.26 (+4.8% Y/Y) topping the $8.15 expectation. Sales of $97.8B (+23.4% Y/Y) exceeded the $96.3B consensus. Continued strength...
Research Alert: Cor Beats Jun-q Eps Expectations, Raises Guidance On U.s. Pharma Profitability
Research Alert: Cor Beats Jun-q Eps Expectations, Raises Guidance On U.s. Pharma Profitability
Aug 6, 2025
05:25 PM EDT, 08/06/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: COR delivered a strong Jun-Q, with EPS of $4.00 vs. $3.34 (+19.8% Y/Y) beating consensus by $0.16. Revenue of $80.7B rose 8.7% Y/Y, 0.7% above consensus. U.S. Healthcare segment sales...
Copyright 2023-2026 - www.financetom.com All Rights Reserved